Chongqing Zhifei Biological Products Co Ltd
SZSE:300122

Watchlist Manager
Chongqing Zhifei Biological Products Co Ltd Logo
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Watchlist
Price: 28.22 CNY -5.21% Market Closed
Market Cap: 67.7B CNY
Have any thoughts about
Chongqing Zhifei Biological Products Co Ltd?
Write Note

Net Margin
Chongqing Zhifei Biological Products Co Ltd

12.9%
Current
23%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.9%
=
Net Income
6B
/
Revenue
46.7B

Net Margin Across Competitors

Country CN
Market Cap 67.6B CNY
Net Margin
13%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 312.7B USD
Net Margin
9%
Country US
Market Cap 158.3B USD
Net Margin
13%
Country US
Market Cap 116.2B USD
Net Margin
-5%
Country US
Market Cap 112.4B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 133.6B AUD
Net Margin
18%
Country US
Market Cap 81.3B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.8B EUR
Net Margin
-14%
No Stocks Found

Chongqing Zhifei Biological Products Co Ltd
Glance View

Market Cap
67.6B CNY
Industry
Biotechnology

Chongqing Zhifei Biological Products Co., Ltd., founded in 1992, has swiftly ascended to become a key player in the Chinese biopharmaceutical landscape, primarily focusing on the development, manufacturing, and commercialization of vaccines and diagnostic products. The company operates with a vision to address pressing public health challenges, and it has established an impressive portfolio that includes vaccines for diseases like hepatitis, influenza, and COVID-19. With a robust research and development (R&D) foundation, Zhifei has secured multiple partnerships and collaborations, further bolstering its innovation pipeline and expanding its market reach. This strategic positioning within China's burgeoning biopharmaceutical sector highlights the company’s commitment to quality and safety, aligning closely with the growing national emphasis on health and disease prevention. For investors, Zhifei represents not just a stake in a successful vaccine manufacturer, but also an opportunity to participate in a transformative phase of public health management in China and beyond. The company’s recent advancements in vaccine technology and its ability to rapidly pivot in response to global health emergencies—exemplified by its expedited COVID-19 vaccine development—underscore its agility and competitive edge in a high-growth market. As the demand for advanced biological products continues to rise globally, Zhifei’s solid financial foundations, coupled with government support for the biopharmaceutical industry, position it as a compelling investment with the potential for substantial long-term returns. The confluence of innovation, strong governmental backing, and a commitment to improving public health makes Chongqing Zhifei a noteworthy candidate for investors looking to tap into the evolving healthcare landscape.

Intrinsic Value
46.22 CNY
Undervaluation 39%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
12.9%
=
Net Income
6B
/
Revenue
46.7B
What is the Net Margin of Chongqing Zhifei Biological Products Co Ltd?

Based on Chongqing Zhifei Biological Products Co Ltd's most recent financial statements, the company has Net Margin of 12.9%.